Document is current

Article History

Received: 9 November 2025

Accepted: 23 December 2025

First Online: 21 January 2026

Declarations

:

: Thiamidol is patented by Beiersdorf AG. The Thiamidol cream 0.2% samples and the study funding were provided by Beiersdorf (Thailand) Co., Ltd. Dr. Ludger Kolbe, an employee of Beiersdorf AG, Hamburg, Germany, contributed to the study’s conceptualization, data curation, provision of resources, supervision, and critical review of the manuscript draft. However, he was not involved in the data analysis or interpretation. We have no other conflicts of interest to declare. Chinmanat Lekhavat, Jinda Rojanamatin, and Mingkwan Suphannaphong have nothing to disclose.

: The study was approved by the Ethics Committee/Institutional Reviewer Board of the Institute of Dermatology, Bangkok, Thailand (approval no. 015/2563). This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Written informed consent to participation was obtained from all participants. Written consent to publication was obtained from all participants whose images are included in the manuscript. The study was prospectively registered at ClinicalTrials.gov (registration no. NCT03926845).

: None of the participating patients were involved in the design, conduct, reporting, or dissemination plans for this research. However, all participants provided informed consent to participation prior to enrollment and were closely monitored throughout the study. Those whose images are shown in the figures also provided consent to the publication of this content. Their clinical outcomes and experiences of our participants were essential to the findings presented in this manuscript.